Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-11T14:41:48+00:00May 9th, 2022|2022 Press Releases, Press Releases| 更多详细信息
Invivoscribe启动资助计划，支持基于序列的免疫系统分析新应用 2021年6月24日wmm2021-12-19T07:20:24+00:00June 24th, 2021|2021 Press Releases, Press Releases| 更多详细信息
在美国、欧洲和中国，Invivoscribe在其设立的参考实验室首次推出12色流式细胞术检测 2021年6月3日|2021年新闻发布，新闻稿wmm2021-12-19T07:20:31+00:00June 3rd, 2021|2021 Press Releases, Press Releases| 更多详细信息
Invivoscribe将在2019年旧金山生物技术展示™上发表演讲wmm2022-01-03T02:52:03+00:00January 3rd, 2019|2019 Press Releases, Press Releases| 更多详细信息
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases| 更多详细信息
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases| 更多详细信息
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases| 更多详细信息
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases| 更多详细信息
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases| 更多详细信息
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases| 更多详细信息
